VIDEO: Trastuzumab deruxtecan shows durable activity in HER2-positive metastatic breast cancer

BySavannah Demko

ByNancy U. Lin, MD

Fact checked byMindy Valcarcel, MS

Trastuzumab deruxtecan showed substantial and durable overall and intracranial clinical activity in patients with HER2-positive metastatic breast cancer, according to results from the DESTINYBreast-12 trial presented at ESMO Congress.

Importantly, trastuzumab deruxtecan, also known as T-DXd, (Enhertu; AstraZeneca, Daiichi Sankyo) exhibited these benefits in a large cohort with stable and active brain metastases, Nancy Lin, MD, from the department of medical oncology at Dana-Farber Cancer Institute, told Healio in a video interview.

“Overall, I think this supports the use of T-DXd in the second-line setting, irrespective of the presence or absence of baseline brain metastases,” Lin said.

Reference:

Lin N, et al. Abstract LBA18. Presented at: European Society for Medical Oncology Congress; Sept. 13-17; Barcelona, Spain.

Published by:

Sources/Disclosures

Collapse

Source: Healio Interviews

Disclosures: Lin reports receiving institutional research support, consulting honoraria, travel and/or royalties from AstraZeneca, Artera Inc., Blueprint Medicines, Daichii-Sankyo, Eisai, Genentech, Janssen, Olema Pharmaceuticals, Pfizer, Merck, Seagen, Stemline/Menarini, Up To Date and Zion Pharmaceuticals.

Take Homes in Breast Cancer

Read more

VIDEO: Trastuzumab deruxtecan shows durable activity in HER2-positive metastatic breast cancer

Reference:

Related Content